Skip to content
S649Senate2021-2022 SessionSame asA2030

End Prior Authorization for Treatment

Official title

“Relates to medication assisted treatment for substance use disorders”

Sponsor Pete HarckhamSD-40+3 co-sponsorsAffects Finance
Status
Senate Floor Calendar
Impact
7/10
Significant
Outcome
Companion signed

Bill progress

Signed via A2030

What's happening

This bill eliminates prior authorization requirements for certain medications used to treat substance use disorders in New York.

Why it matters

  1. Broadens access to key addiction medications. By removing prior authorization for all buprenorphine products, methadone, and long-acting injectable naltrexone, the bill makes it easier for patients to start or maintain evidence-based treatment for substance use disorders without administrative delays.

  2. Responds to urgent public health needs. Streamlining access can help address the opioid crisis by reducing treatment gaps, which are known to increase risk of relapse, overdose, and death among individuals with substance use disorders.

  3. Reduces bureaucratic barriers for providers and patients. Healthcare providers can prescribe medication-assisted treatment according to best-practice guidelines without waiting for insurer approval, potentially leading to more timely and effective care.

  4. Establishes a consistent statewide standard. The bill overrides exceptions in existing law (such as for non-preferred drug forms), ensuring that insurance plans and managed care providers uniformly cannot impose prior authorization for these medications, regardless of drug formulary status.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

End Prior Authorization for Treatment

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Pete Harckham

Senator · Senate District 40

Chair, Alcoholism And Substance Abuse

History

  1. Substituted by A2030
  2. Ordered to third reading cal.1294
  3. Committee discharged and committed to rules
  4. Reported and committed to finance
  5. Print number 649a
  6. Amend and recommit to health
  7. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A2030Assembly

End Medication Treatment Delays

Signed by Governor · Sponsor Linda Rosenthal

Impact 7 · SignificantSigned into law

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

649--A

2021-2022 Regular Sessions

IN SENATE (Prefiled)

January 6, 2021

Introduced by Sen. HARCKHAM -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the social services law and the public health law, in relation to medication for the treatment of substance use disorders

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (gg) to read as follows:

(gg) all buprenorphine products, methadone or long acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder. Such medication assisted treatment shall not be subject to any prior authorization mandate.

§ 2. Subdivision 26-b of section 364-j of the social services law, as added by section 4 of part B of chapter 69 of the laws of 2016, is amended to read as follows:

26-b. Managed care providers shall not require prior authorization for [an initial or renewal prescription for buprenorphine or injectable naltrexone for detoxification or maintenance treatment of opioid addiction unless the prescription is for a non-preferred or non-formulary form of the drug or as otherwise required by section 1927(k)(6) of the Social Security Act] any buprenorphine products, methadone or long acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD00371-03-1

S. 649--A 2

§ 3. Subdivision 10 of section 273 of the public health law, as amended by section 7 of part GG of chapter 56 of the laws of 2020, is amended to read as follows:

10. Prior authorization shall not be required for [an initial or renewal prescription for buprenorphine or injectable naltrexone for detoxification or maintenance treatment of opioid addiction unless the prescription is for a non-preferred or non-formulary form of such drug as otherwise required by section 1927(k)(6) of the Social Security Act. Further, prior authorization shall not be required for] any buprenorphine products, methadone, [when used for opioid use disorder and administered or dispensed in an opioid treatment program] or long acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder.

§ 4. This act shall take effect on the ninetieth day after it shall have become a law; provided, however, that the amendments to subdivision 26-b of section 364-j of the social services law made by section two of this act shall not affect the repeal of such section, and shall be deemed repealed therewith.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the social services law and the public health law, in relation to medication for the treatment of substance use disorders

Purpose

This legislation will expand access to medications that treat substance use disorders.

Summary of specific provisions

Section one amends subdivision 2 of section 365-a of the social services law by adding a new paragraph (gg)

Section two amends subdivision 26-b of section 364-j of the social services law. Section three amends subdivision 10 of section 273 of the public health law. Section four sets the effective date.

Justification

Medication assisted treatment, or MAT, is an evidence-based treatment method that uses FDA approved medications to help an individual overcome a substance use disorder. Medications such as methadone, buprenorphine and naltrexone have all been used successfully and more treatment providers are turning to this approach given its ability to reduce and block cravings, ease withdrawal symptoms and otherwise enable an indi- vidual to reach recovery more easily. However, medications used in MAT programs are not interchangeable and each patient may respond different- ly, therefore it is imperative that this choice be left to the patient and their doctor to determine the appropriate medication. Under current law, individuals under Medicaid are not given the opportunity to access all forms of medication assisted treatment and may be limited to one specific type. This legislation would allow individuals under Medicaid the ability to access whichever MAT medication is most beneficial to them and their needs, without utilization control, mandated prior authorization, or lifetime limits.

Legislative history

2019: A.7246-B/S.5935-A - Vetoed

Fiscal implications

Undetermined.

Effective date

This act shall take effect in 90 days.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.